Physician profile
John J Black
NPI 1710340203
$1,730.02
in general payments reported to CMS, 2019-2025
14 companies · $559 in 2025
The $559 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $134 · 2021: $23.00 · 2022: $175 · 2023: $377 · 2024: $336 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $385.94 | 2024-2025 | Giapreza, Zevtera |
| Pfizer INC. | $264.54 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $210.32 | 2020-2023 | Xarelto |
| Davol INC. | $160.12 | 2025 | Arista |
| Merck Sharp & Dohme LLC | $124.99 | 2025 | Zerbaxa |
| Vertex Pharmaceuticals Incorporated | $124.50 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $102.01 | 2020 | |
| Edwards Lifesciences Corporation | $93.80 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Ucb, INC. | $66.19 | 2023-2024 | Briviact |
| E.R. Squibb & Sons, L.L.C. | $53.95 | 2019-2023 | Eliquis |
| Abbott Laboratories | $44.90 | 2023 | Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.05 | 2022 | |
| Boston Scientific Corporation | $39.85 | 2023 | Watchman Flx |
| Novo Nordisk INC | $14.86 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.